Renal flares are common in patients with severe proliferative lupus nephritis treated with pulse immunosuppressive therapy: Long-term followup of a cohort of 145 patients participating in randomized controlled studies

Arthritis and Rheumatism

Volumn 46, Issue 4, 2002, Pages 995-1002

  Illei, G G ^a   Takada, K ^a   Parkin, D ^a   Austin, H A ^b   Crane, M ^a   Yarboro, C H ^a   Vaughan, E M ^b   Kuroiwa, T ^a   Danning, C L ^a   Pando, J ^a   Steinberg, A D ^c   Gourley, M F ^d   Klippel, J H ^a   Balow, J E ^b   Boumpas, D T ^a,e  

^a NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES   (United States)

^b NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES   (United States)

^c NOBLIS   (United States)

^d WASHINGTON HOSPITAL CENTER   (United States)

^e UNIVERSITY OF CRETE   (Greece)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOPHOSPHAMIDE; IMMUNOSUPPRESSIVE AGENT; METHYLPREDNISOLONE;

ADULT; ARTICLE; COHORT ANALYSIS; DISEASE PREDISPOSITION; DRUG RESPONSE; FEMALE; FOLLOW UP; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; KIDNEY FAILURE; LUPUS ERYTHEMATOSUS NEPHRITIS; MAJOR CLINICAL STUDY; MALE; NEGRO; NEPHRITIS; PRIORITY JOURNAL; PROTEINURIA; RACE DIFFERENCE; RISK FACTOR;

ADULT; ANTI-INFLAMMATORY AGENTS; COHORT STUDIES; CYCLOPHOSPHAMIDE; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; KIDNEY FAILURE, CHRONIC; LUPUS NEPHRITIS; MALE; METHYLPREDNISOLONE; PREDICTIVE VALUE OF TESTS; PREVALENCE; PULSE THERAPY, DRUG; RECURRENCE; TREATMENT OUTCOME;

EID: 0036222879     PISSN: 00043591     EISSN: None     Source Type: Journal    
DOI: 10.1002/art.10142     Document Type: Article

References (30)

1. Treatment of diffuse proliferative lupus nephritis with prednisone and combined prednisone and cyclophosphamide
2. Therapy of lupus nephritis: Controlled trial of prednisone and cytotoxic drugs
3. Controlled trial of pulse methylprednisolone versus two regimens of pulse cyclophosphamide in severe lupus nephritis
4. A controlled trial of plasmapheresis therapy in severe lupus nephritis
5. Intravenous pulse cyclophosphamide treatment of severe lupus nephritis: A prospective five-year study
6. New York University/Hospital for Joint Diseases experience with intravenous cyclophosphamide treatment: Efficacy in steroid unresponsive lupus nephritis
7. Cyclophosphamide therapy for lupus nephritis: Poor renal survival in black Americans
8. Methylprednisolone and cyclophosphamide, alone or in combination, in patients with lupus nephritis: A randomized, controlled trial
9. Intermittent intravenous cyclophosphamide arrests progression of the renal chronicity index in childhood systemic lupus erythematosus
10. Lupus nephritis
11. The prognosis of lupus nephritis in African-Americans: A retrospective analysis
12. Sequential therapy for diffuse proliferative and membranous lupus nephritis: Cyclophosphamide and prednisolone followed by azathioprine and prednisolone
13. Cumulative rate of relapse of lupus nephritis after successful treatment with cyclophosphamide
14. "Nephritic flares" are predictors of bad long-term renal outcome in lupus nephritis
15. Flare of childhood lupus nephritis after discontinuing treatment with intravenous pulse cyclophosphamide
16. Remission, relapse, and re-remission of proliferative lupus nephritis treated with cyclophosphamide
17. Measurement of increases in anti-double-stranded DNA antibody levels as a predictor of disease exacerbation in systemic lupus erythematosus: A long-term, prospective study
18. Serum C3 levels are diagnostically more sensitive and specific for systemic lupus erythematosus activity than are serum C4 levels
19. Diffuse proliferative lupus nephritis: Identification of specific pathologic features affecting renal outcome
20. Regression methods and life tables
21. Nonparametric estimation from incomplete observations
22. The phenotype of SLE associated with complete deficiency of complement isotype C4A
23. Relationship between C4 null genes, HLA-D region antigens, and genetic susceptibility to systemic lupus erythematosus in Caucasian and black Americans
24. C4A deficiency due to a 2 bp insertion is increased in patients with systemic lupus erythematosus
25. Fcγ RIIA alleles are heritable risk factors for lupus nephritis in African Americans
26. Familial clustering of end-stage renal disease in blacks with HIV-associated nephropathy
27. Familial predisposition to nephropathy in African-Americans with non-insulin-dependent diabetes mellitus
28. Familial clustering of end-stage renal disease in blacks with lupus nephritis
29. Genetic linkage analysis of growth factor loci and end-stage renal disease in African Americans
30. High-risk features of lupus nephritis: Importance of race and clinical and histological factors in 166 patients